await may investor event clariti
revenue ep line consensu slightli lower sale
chca chci off-set better expect perform soon-
to-be-separ rx pharma guidanc offer come may
analyst day howev base new mgt focu oper effici
innov reduc revenu est new pt
new ceo kessler quickli dissect ail begun address
issu solut provid may analyst day
receiv invest commun
mr kessler quickli taken charg lot energi like fact
openli discuss miscu past view co seemingli
underinvest technolog custom servic capac new product develop
attribut cornerston prgo success year lay
feet two larg acquisit overpaid
also distract rest organ omega mr
kessler alreadi made key senior hire area consum market
 innov busi intellig may senior management team
present new roadmap detail progress alreadi made date
financi guidanc end call ceo state think go
see lot activ expect would like talk
promis futur would like bring action said increas
competit price headwind lack clear rx over-the-counter switch horizon
still unclear us turn around least near term
like heard thu far eagerli await action plan
earlier week management announc first challeng process irish
revenu make assess management view assess incorrect matter
law pursu avail avenu challeng assess entir
proceed includ administr legal challeng well potenti
appeal process could take year nonetheless still potenti signific issu
co spoke irish tax expert indic beyond back
tax addit interest alreadi could levi irish government prevail
top penalti could levi gener penalti penalti
legaci determin intent misl irish revenu thu total
bill could balloon worst-cas scenario scenario seem unlik
rule point
financi restat reflect divestitur tysabri
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
vertic integr global healthcar compani
develop manufactur distribut over-the-count
over-the-counter healthcar product gener rx drug co
largest global manufactur store brand privat label over-the-counter
pharmaceut product infant formula benefit
signific macro trend consum accept
store brand omega brand european over-the-counter busi
met expect plan separ divest
spin etc gener busi uncertain
unlock valu sharehold
potenti extern pressur sharehold activ
take-over specul
new product launch chc busi rx over-the-counter
potenti bolt-on acquisit chc self
success p-iv challeng larg brand rx product
gener price improv slightli base erod high-
chca busi grow low singl digit rate driven new
chci margin continu steadili expand
meaning growth d/new product success
develop self busi
chc segment realiz stronger anticip net sale
cost save restructur
litig win potenti earlier expect gener
chci return growth faster expect
gener price environ continu impact rx pharma
chci remain drag prgo busi
lower anticip gross margin expans due
pleas see import disclosur inform page report
financi summari market data
estim valuat
financi restat reflect divestitur tysabri
pleas see import disclosur inform page report
quarterli varianc tabl except per share data
await either sale spin rx busi
littl activ busi develop front
return tuck in may of year
call manag offer updat plan separ gener rx
busi move full steam ahead plan stand-alone consum
product comp meanwhil manag place renew emphasi return
tuck acquisit way help jump start growth near medium term
tangibl exampl new area move self care banner includ would
ad probiot dietari supplement co nutrit portfolio product
medic over-the-counter skin care person care etc would promot well prevent
diseas management indic look privat public co us
progress appar alreadi made
streamlin exist busi
clearli mr kessler indic chci busi
histor manag amalgam mani small busi
good progress alreadi made toward restructur busi mani
pleas see import disclosur inform page report
unprofit product geographi exit said management highlight
organiz complex key on-going issu co
pleas see import disclosur inform page report
